Treatment of ibrutinib-resistant CLL cells with mutations at C481 using NC-1 led to a decrease in BTK and pBTK levels, as well as in phosphorylation of Akt and ERK. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.